Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI FOLFOX + Irinotecan vs Systemic FOLFOXIRI in RAS-mutated mCRC
NCT05727163Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Remission Rate at 48 months. Started Jul 2022; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05727163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727163.